Urovant Sciences cashes in $75m in licence deal from Pierre Fabre
French drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences’ drug vibegron for the treatment of overactive bladder in Europe.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2127 entries already.
Entries by Thomas Gabrielczyk
CureVac NV sues BioNTech for IP infringement
German mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents.
French Ipsen falls after Epizyme take-over announcement
Shares of French drugmaker Ipsen fell by 4.4% at Euronext Paris after the company announced to take over US cancer specialist Epizyme Inc. for $247m.
TWB announces winners in industrial biotech start-up contest
At the end of the TWB Start-up day, which was attended by more than 200 biotech professionals, two industrial biotechnology companies were awarded prizes worth €50,000.
BIONTech breaks ground for manufacturing site in Rwanda
BioNTech SE has announced it is going to ship the first containers for mRNA malaria vaccine production from this year’s end toKigall.
Cannabis players Canify AS and Bavaria Weed merge to form Canify AG
In an effort to become a major player in Europe’s growing pharmaceutical-grade cannabis market, Danish Canify AS and Bavaria Weed GmbH merge to form Canify AG.
Unilever launches $120m venture with Genomatica
Under the $120m deal, Genomatica and Unilever will scale plant- and waste-based alternative to palm oil and fossil fuels.
Roche obtains special authorisation for bispecific antibody
Roche obtained from European Medicine Agency (EMA) a special authorization (conditional approval) for new bispecific antibody Lunsumio for treatment of relapsed or refractory follicular (R/R) lymphoma (FL) – a B-cell cancer. Data for authorization are based on a survey from a phase I/II trail. The high unmet need of this indication led to that early decision, it is said.
French ImCheck get´s a USD103m check by Pfizer and a pack of VCs
ImCheck Therapeutics located in Marseille, France, announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. Kurma Partners, Eurazeo, Gimv, Pfizer, Bpifrance through its Innobio 2 and Large Venture funds, Wellington Partners, Pureos Bioventures, Agent Capital and Alexandria Venture Investments are invested already. Invus and The Leukemia & Lymphoma
Society Therapy Acceleration Program also joined the round as new investors.
$50m for London CHARM Therapeutics for deep minded folding expertise
CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology.